Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application

Human Gene Therapy

Volumn 18, Issue 12, 2007, Pages 1253-1260

  Quintás Cardama, Alfonso ^a   Yeh, Raymond K ^a   Hollyman, Daniel ^a   Stefanski, Jolanta ^a   Taylor, Clare ^a   Nikhamin, Yan ^a   Imperato, Gavin ^a   Sadelain, Michel ^a   Rivière, Isabelle ^a   Brentjens, Renier J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Box 242 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

192Z1 CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANALYTIC METHOD; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; RETROVIRUS; T LYMPHOCYTE; TEMPERATURE; VIRAL GENE DELIVERY SYSTEM;

CENTRIFUGATION; GENE THERAPY; GENETIC VECTORS; HUMANS; RETROVIRIDAE; T-LYMPHOCYTES; TEMPERATURE; TRANSDUCTION, GENETIC;

EID: 37149001207     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.088     Document Type: Article

References (25)

1. AYUK, F.A., LI, Z., KÜHLCKE, K., LINDEMANN, C., SCHADE, U.M., ECKERT, H.-G., ZANDER, A.R., and FEHSE, B. (1999). Establishment of an optimized gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Ther. 6, 1788-1792.
2. BLAESE, R.M., CULVER, K.W., MILLER, D., CARTER, C.S., FLEISHER, T., CLERICI, M., SHEARER, G., CHANG, L., CHIANG, Y., TOLTOSHEV, P., GREENBLATT, J.J., ROSENBERG, S.A., KLEIN, H., BERGER, M., MULLEN, C.A., RAMSEY, W.J., MUUL, L., MORGAN, R.A., and ANDERSON, W.F. (1995). Lymphocyte-directed gene therapy for ADA-SCID: Initial trial after 4 years. Science 270, 475-480.
3. BONINI, C., FERRARI, G., VERZELETTI, S., SERVIDA, P., ZAPPONE, E., RUGGIERI, L., PONZONI, M., ROSSINI, S., MAVILIO, F., TRAVERSARI, C., and BORDIGNON, C. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724.
4. BORDIGNON, C., NOTARANGELO, L.D., NOBILI, N., FERRARI, G., CASORATI, G., PANINA, P., MAZZOLARI, E., MAGGIONI, D., ROSSI, C., SERVIDA, P., UGAZIO, A.G., and MAVILIO, F. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270, 470-475.
5. BRENTJENS, R.J., LATOUCHE, J.-B., SANTOS, E., MARTI, F., GONG, M.C., LYDDANE, C., KING, P.D., LARSON, S., WEISS, M., RIVIÈRE, I., and SADELAIN, M. (2003). Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279-286.
6. BRENTJENS, R.J., SANTOS, E., NIKHAMIN, Y., YEH, R., MATSUSHITA, M., LAPERLE, K., QUINTAS-CARDAMA, A., LARSON, S., and SADELAIN, M. (2007). Successful eradication of systemic, acute lymphoblastic leukemia xenografts by genetically targeted t cells. Clin. Cancer Res. 13, 5426-5435.
7. BUNNELL, B.A., MUUL, L.M., DONAHUE, R.E., BLAESE, R.M., and MORGAN, R.A. (1995). High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 92, 7739-7743.
8. CULVER, K., CORNETTA, K., MORGAN, R., MORECKI, S., AEBERSOLD, P., KASID, A., LOTZE, M., ROSENBERG, S.A., ANDERSON, W.F., and BLAESE, R.M. (1991). Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc. Natl. Acad. Sci. U.S.A. 88, 3155-3159.
9. HANENBERG, H., XIAO, X.L., DILLOO, D., HASHINO, K., KATO, I., and WILLIAMS, D.A. (1996). Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2, 876-882.
10. HWU, P., YANNELLI, J., KRIEGLER, M., ANDERSON, W.F., PEREZ, C., CHIANG, Y., SCHWARTZ, S., COWHERD, R., DELGADO, C., MULÉ, J., and ROSENBERG, S.A. (1993). Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α cDNA for the gene therapy of cancer in humans. J. Immunol. 150, 4104-4115.
11. KERSHAW, M.H., WESTWOOD, J.A., PARKER, L.L., WANG, G., ESHHAR, Z., MAVROUKAKIS, S.A., WHITE, D.E., WUNDERLICH, J.R., CANEVARI, S., RODGERS-FREEZER, L., CHEN, C.C., YANG, J.C., ROSENBERG, S.A., and HWU, P. (2006). A phase I study on adoptive immunotherapy using gene modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115.
12. KOTANI, H., NEWTON, P.B., III, ZHANG, S., CHIANG, Y.L., OTTO, E., WEAVER, L., BLAESE, R.M., ANDERSON, W.F., and MCGARRITY, G.J. (1994). Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5, 19-28.
13. KÜHLCKE, K., FEHSE, B. SCHILZ, A., LOGES, S., LINDEMANN, C., AYUK, F., LEHMANN, F., STUTE, N., FAUSER, A.A., ZANDER, A.R., and ECKHERT, H.G. (2002). Highly efficient retroviral gene transfer based on centrifugation- mediated vector preloading of tissue culture vessels. Mol. Ther. 5, 473-478.
14. LAMANA, M.L., SEGOVIA, J.C., GUENECHEA, G., and BUEREN, J.A. (2001). Systematic analysis of clinically applicable conditions leading to a high efficiency of transduction and transgene expression in human T cells. J. Gene Med. 3, 32-41.
15. LAMERS, C., VAN ELZAKKER, P., LANGEVELD, S., SLEIJFER, S., and GRATAMA, J. (2006). Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for immunogene therapy for metastatic renal cell carcinoma: GMP controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene. Cytotherapy 8, 542-553.
16. MAHER, J., BRENTJENS, R.J., GUNSET, G., RIVIÈRE, I., and SADELAIN, M. (2002). Human T-lymphocyte cytoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20, 70-75.
17. MILLER, D.G., ADAM, M.A., and MILLER, A.D. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10, 4239-4242.
18. MORGAN, R.A., DUDLEY, M.E., WUNDERLICH, J.R., HUGHES, M.S., YANG, J.C., SHERRY, R.M., ROYAL, R.E., TOPALIAN, S.L., KAMMULA, U.S., RESTIFO, N.P., ZHENG, Z., NAHVI, A., DE VRIES, C.R., ROGERS-FREEZER, L.J., MAVROUKAKIS, S.A., and ROSENBERG, S.A. (2006). Cancer regression inpatients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
19. MOVASSAGH, M., BOYER, O., BURLAND, M.C., BURLAND, M.-C., LECLERCQ, V., KLATZMANN, D., and LEMOINE, F.M. (2000). Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. Hum. Gene Ther. 11, 1189-1200.
20. ONODERA, M., ARIGA, T., KAWAMURA, N., KOBAYASHI, I., OHTSU, M., YAMADA, M., TAME, A., FURUTA, H., OKANO, M., MATSUMOTO, S., KOTANI, H., MCGARRITY, G.J., BLAESE, R.M., and SAKIYAMA, Y. (1998). Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91, 30-36.
21. ORY, D.S., NEUGEBOREN, B.A., and MULLIGAN, R.C. (1996). A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. (1996). Proc. Natl. Acad. Sci. U.S.A. 93, 11400-11406.
22. POLLOK, K.E., HANENBERG, H., NOBLITT, T.W., SCHROEDER, W.L., KATO, I., EMANUEL, D., and WILLIAMS, D.A. (1998). High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J. Virol. 72, 4882-4892.
23. PRZYBYLOWSKI, M., HAKAKHA, A., STEFANSKI, J., HODGES, J., SADELAIN, M., and RIVIÈRE, I. (2006). Production scale-up and validation of packaging cell clearance of clinical-grade retroviral stocks produced in cell factories. Gene Ther. 13, 95-100.
24. RIVIÈRE, I., BROSE, K., and MULLIGAN, R.C. (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. U.S.A. 92, 6733-6737.
25. SPRINGETT, G.M., MOEN, R.C., ANDERSON, S., BLAESE, R.M., and ANDERSON, W.F. (1989). Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J. Virol. 63, 3865-3869.